PRF Technologies Ltd 6-K, filed Nov 9, 2020
PRF Technologies Ltd. (PRFX)
About this 6-K
PRF Technologies Ltd filed this 6-K on November 9, 2020.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of November, 2020
Commission File Number: 001-39481
PainReform Ltd.
(Translation of registrant’s name into English)
60C Medinat Hayehudim
Herzliya, 4676670
Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
PainReform Ltd
Explanatory Note
On November 9, 2020, PainReform Ltd. issued a press release titled: “PainReform Welcomes Senior Pharmaceutical Executive and Venture Capitalist Augustine Lawlor to Board of Directors.”
A copy of this press release is furnished herewith as Exhibit 99.1 and incorporated herein by reference
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Date: November 9, 2020 | PAINREFORM LTD. | |
| By: | /s/ Eli Hazum | |
| Eli Hazum Chief Executive Officer | ||
2
Exhibit 99.1
PainReform Welcomes Senior Pharmaceutical
Executive and
Venture Capitalist Augustine Lawlor to Board of Directors
HERZLIYA, Israel – November XX, 2020 – PainReform Ltd. (NasdaqCM: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, welcomes Augustine Lawlor as a member of the Company’s Board of Directors following its recent initial public offering.
Mr. Lawlor has served as Chief Operating Officer of Leap Therapeutics, Inc., an oncology company, since January 2016 and has been a Managing Director of HealthCare Ventures since 2000. From 1997 to 2000, he served as Chief Operating Officer of LeukoSite, Inc., a biotechnology company acquired by Millennium Pharmaceuticals Inc. in 1999. Prior to joining LeukoSite, Mr. Lawlor was Chief Financial Officer and Vice President of Corporate Development for Alpha-Beta Technologies, Inc., a company that specializes in electronics design, development, manufacturing and system obsolescence issues. He has held similar positions at both BioSurface Technologies Corporation, a company that provides products for biofilm investigations, and Armstrong Pharmaceuticals, a division of Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company. Mr. Lawlor was previously a management consultant with KPMG. He is currently Chairman of the Board of Catalyst Biosciences, Inc. and a director of Cardiovascular Systems, Inc., biopharmaceutical companies which are listed on Nasdaq. Mr. Lawlor received his Master’s degree in Public and Private Management from Yale University and a B.A. degree from the University of New Hampshire.
Dr. Ehud Geller, Chairman of the Board, commented, “Gus Lawlor is an important addition to our Board, as he is a seasoned and successful healthcare investor and venture capitalist and brings extensive experience in the pharmaceutical industry, including oversight of finance, business development, and manufacturing functions. He has been involved in numerous mergers and acquisitions, including the billion-dollar sale/merger of Leukosite, Inc. with Millenium Pharmaceuticals. He also oversaw the sales of Armstrong Pharmaceuticals to Medevac, and Biosurface Technology to Genzyme. As a venture capitalist, he managed an investment portfolio of over one billion dollars in committed capital. We believe that his healthcare, financial and capital markets experience will be of tremendous benefit to us as we advance PRF-110 through pivotal Phase 3 trials and seek to maximize the value of the asset. Importantly, assuming our planned Phase 3 trial is successful, we believe PRF-110 has the potential to become the standard-of-care within the multi-billion post-operative pain treatment market and represents a highly attractive alternative to systemic opioids.”
About PainReform
PainReform is a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics. PRF-110, the Company’s lead product, is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed prior to closure to provide localized and extended post-operative analgesia. The Company’s proprietary extended release drug-delivery system is designed to provide an extended period of post-surgical pain relief without the need for repeated dose administration while reducing the potential need for the use of opiates.
Notice Regarding Forward-Looking Statements
This press release contains certain forward-looking statements, including statements with regard to PainReform’s proposed clinical trials. Words such as “expects,” “anticipates” and “intends” or similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions and no assurance can be given that the clinical trials discussed above will be successfully completed. Completion of the proposed clinical trials are subject to numerous factors, many of which are beyond the control of the Company, including, without limitation, failure of the clinical trials, and the risk factors and other matters set forth in the Company’s recent prospectus included in the registration statement, in the form last filed with the SEC. PainReform undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.
Contact:
Crescendo Communications, LLC
Tel: 212-671-1021
Email: prfx@crescendo-ir.com